Protez Pharmaceuticals develops new antibiotics to combat the growing problem of drug resistance, as well as agents that improve the efficacy of current antibiotics.

Our focus is difficult-to-treat hospital-based infections. In the United States alone, over eight million people are hospitalized with bacterial infections each year, accounting for greater then 90 million days of therapy. Many of these infections are serious and extremely difficult to treat. Additionally, of great concern to health care professionals is the fact that life-threatening microbes have developed resistant strains that no longer respond to any of the available antibiotics.

We at Protez are committed to meeting the urgent need for new antibiotics by applying our expertise in anti-infectives as well as experience in discovering, developing and marketing pharmaceuticals.

PZ-601, our lead antibiotic entering Phase 2 clinical trials, is a novel carbapenem with an antimicrobial spectrum that includes multidrug-resistant Gram positive bacteria (methicillin-resistant Staphylococcus aureus, MRSA; Enterococcus faecium) and extended-spectrum beta-lactamase-producing Gram negative bacteria (ESBLs).